Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing

Dana-Farber Cancer Institute2 sites in 1 country40 target enrollmentMay 1, 2023

ConditionsGenetic Predisposition to Disease Genetic Predisposition

InterventionsNest Platform

Overview

Phase: Not Applicable
Intervention: Nest Platform
Conditions: Genetic Predisposition to Disease
Sponsor: Dana-Farber Cancer Institute
Enrollment: 40
Locations: 2
Primary Endpoint: Proportion of Clinician Utilization (Feasibility)
Status: Recruiting
Last Updated: 8 days ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This research is being done to develop the electronic platform Nest for young adults (ages 18-39) who have had prior cancer genetic testing. The platform will give patients and their clinicians access to continuously updated information about both pathogenic variants and variants of uncertain significance (VUS).

The name of the intervention used in this research study is:

Nest portal (electronic platform for patients and clinicians)

Detailed Description

The goal of the electronic platform Nest is to help patients understand and manage genetic test results and recommended care and to help clinicians with access to results and recommendations, facilitating orders, and documentation. The portal has two parts, one for participants and one for clinicians. For the first phase of the study, participants will give their feedback on the Nest portal's content and processes that will guide refinement of the portal. The Pilot phase will test the feasibility and acceptability of the intervention. The research study procedures include a baseline survey, using the portal after receiving a brief orientation from the study team, a follow-up survey, and then a 30-minute interview. Participants will be in this research study for up to 2 hours. It is expected that about 40 people will take part in this research study. The electronic platform is being developed by Nest Genomics.

Registry

clinicaltrials.gov

Start Date

May 1, 2023

End Date

July 30, 2026

Last Updated

8 days ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Dana-Farber Cancer Institute

Responsible Party

Principal Investigator

Jennifer Mack, MD

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

Inclusion Criteria

•YA Patients:
•Ages 18-39 years, inclusive.
•Has had previous cancer genetic testing, with a finding of a pathogenic variant or VUS; patient has previously received results from the clinical team.
•English-speaking and -reading.
•Receiving care at DFCI.
•Not undergoing active cancer therapy at the time of approach.
•Clinicians:
•Cancer risk physicians (oncologists, gastroenterologists, geneticists), oncologists, nurse practitioners, physician assistants, or genetic counselors.
•English-speaking and -reading.
•Cares for YAs aged 18-39 with cancer risk syndromes.

Exclusion Criteria

Not provided

Arms & Interventions

Nest Refinement Phase

20 participants and clinicians will complete study procedures as outlined: * Nest portal orientation and access. * Semi-structured, 30-minute interviews. Solicited feedback on content and processes will refine the intervention for a pilot phase.

Intervention: Nest Platform

Nest Pilot Phase

10 Participants and 10 clinicians will complete study procedures as outlined: * Baseline survey (participant). * Standard clinic visit. * Nest portal orientation and access (participant and clinician). * Post-visit survey (participant and clinician). * Brief, 30-minute, semi-structured interview (participant and clinician).

Intervention: Nest Platform